TCR2 Therapeutics Inc
NASDAQ:TCRR
TCR2 Therapeutics Inc
Research & Development
TCR2 Therapeutics Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
TCR2 Therapeutics Inc
NASDAQ:TCRR
|
Research & Development
-$98.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is TCR2 Therapeutics Inc's Research & Development?
Research & Development
-98.4m
USD
Based on the financial report for Dec 31, 2022, TCR2 Therapeutics Inc's Research & Development amounts to -98.4m USD.
What is TCR2 Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-59%
Over the last year, the Research & Development growth was -34%. The average annual Research & Development growth rates for TCR2 Therapeutics Inc have been -38% over the past three years , -59% over the past five years .